{
    "clinical_study": {
        "@rank": "83943", 
        "arm_group": {
            "arm_group_label": "suspension for injection", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "To assess immunogenicity of a single intramuscular injection of Fluval AB suspension for\n      injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 \u03bcgHA/0.5mL\n      of seasonal A/H1N1, A/H3N2 and B influenza antigens each), as measured by haemagglutination\n      inhibition (HI) test."
        }, 
        "brief_title": "Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection", 
        "condition": "Seasonal Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult persons aged 18 to 59 years, elderly persons aged \u226560 years from both sexes,\n             mentally competent;\n\n          -  Are in good health (as determined by vital signs and existing medical condition) or\n             are in stable medical condition. Subjects will not be excluded with known adequately\n             treated clinically significant organ or systemic diseases (e.g. asthma or diabetes),\n             such that, in the opinion of the investigator, the significance of the disease will\n             not compromise the subject's participation in the study;\n\n          -  Female volunteers aged 18-59 years (i.e. participants of childbearing potential) with\n             a negative result from the urine pregnancy test prior to vaccination who agrees to\n             use an acceptable contraception method or abstinence throughout the trial and not\n             become pregnant for the duration of the study;\n\n          -  Capability of participants to understand and comply with planned study procedures;\n\n          -  Participants provide written Informed Consent (IC) prior to initiation of study\n             procedures;\n\n          -  Absence of existence of any exclusion criteria.\n\n        Exclusion Criteria:\n\n          -  Pregnancy, breast feeding or positive urine pregnancy test at baseline prior to\n             vaccination. Female subjects who are able to bear children but not willing to use an\n             acceptable contraception method for the duration of the study.\n\n          -  Known hypersensitivity to eggs, chicken protein, thiomersal, formaldehyde,\n             gentamycin, ciprofloxacin, neomycin, vancomycin or any other component of the\n             vaccine;\n\n          -  History of Guillain-Barr\u00e9 syndrome;\n\n          -  History of neurological symptoms or signs, or anaphylactic shock following\n             administration of any vaccine;\n\n          -  Serious disease, such as cancer, autoimmune disease, advanced arteriosclerotic\n             disease, complicated diabetes mellitus, acute or progressive hepatic disease, acute\n             or progressive renal disease, congestive heart failure;\n\n          -  Immunosuppressive therapy within 36 months prior to vaccination;\n\n          -  Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids;\n\n          -  Receipt of immunostimulants;\n\n          -  Receipt of parenteral immunoglobulin, blood products and/or plasma derivate within 3\n             months prior to vaccination;\n\n          -  Suspected or known HIV, HBV or HCV infection;\n\n          -  Acute disease and/or axillary temperature \u226537oC within 3 days prior to vaccination;\n\n          -  Vaccine therapy within 4 weeks prior to vaccination;\n\n          -  Influenza vaccination (any kind) within 6 months prior to vaccination;\n\n          -  Experimental drug therapy within 4 weeks prior to vaccination;\n\n          -  Concomitant participation in another clinical study;\n\n          -  Any condition which, in the opinion of the investigator, may interfere with the\n             evaluation of the study;\n\n          -  Past or current psychiatric disease of the volunteer that upon judgement of the\n             investigator may have effect on the objective decision-making of the volunteer;\n\n          -  Alcohol or drug abuse of the participant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863849", 
            "org_study_id": "FluvalAB-H-YL2013"
        }, 
        "intervention": {
            "arm_group_label": "suspension for injection", 
            "description": "Single intramuscular injection of Fluval AB and collect serum samples for immunogenicity", 
            "intervention_name": "Fluval AB suspension for injection", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "uncontrolled,", 
            "open,", 
            "multi-centre", 
            "immunogenicity and tolerability", 
            "two groups according to age (18-59 years and \u226560 years)"
        ], 
        "lastchanged_date": "May 28, 2013", 
        "number_of_arms": "1", 
        "official_title": "Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 \u03bcgHA/Strain/0.5mL) for the Use in the Season 2013/2014 in Adult and Elderly Subjects", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To assess immunogenicity of a single intramuscular injection of Fluval AB suspension for injection (15 \u03bcgHA/0.5mL of seasonal A/H1N1, A/H3N2 and B influenza antigens each), as measured by haemagglutination inhibition (HI) test.", 
            "safety_issue": "Yes", 
            "time_frame": "21-28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863849"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Omninvest Vaccine Manufacturing, Researching and Trading Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Omninvest Vaccine Manufacturing, Researching and Trading Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}